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Abstract
Rationale, aims and objectives Antipsychotics are approved treatment for severe condi-
tions and have serious side effects. Antipsychotics are often prescribed off-label. Although
a substantial proportion of antipsychotics are prescribed in primary care, it is largely
unknown what motivates the general practitioner (GP) to initiate antipsychotic treatment.
Therefore, we sought to examine the relation between pre-defined, licensed as well as
off-label, reasons for antipsychotic treatment and the initiation of this treatment by the GP
as well as report registration and incidence of antipsychotic treatment in general practice.
Methods In a case–control study, 723 patients selected from an electronic database and
with a new antipsychotic prescription were compared with 3615 controls receiving any
other new prescription. Using logistic regression, six pre-defined categories of International
Classification of Primary Care (ICPC) codes (‘psychosis’, ‘depression and anxiety’, ‘sleep-
ing disorders’, ‘acute stress and surmenage’, ‘dementia’ and ‘somatic indications’) were
associated with initiating antipsychotic treatment.
Results All, including off-label, categories were significantly related to initiating anti-
psychotic treatment. The incidence of initiating antipsychotic therapy was 1.28 per 1000
persons per year (95% confidence interval: 1.09, 1.48). GPs registered an ICPC code in
50% and prescribed typical antipsychotics in 90% of the cases. Prescription of atypical
antipsychotics increased almost threefold over the study period.
Conclusions The results suggest that GPs prescribe antipsychotics off-label. Despite
serious side effects and relatively infrequent occurrence in Dutch general practices, GPs
seem imprecise in underpinning and registrating the initiation of antipsychotic treatment.
GPs increasingly prescribe atypical antipsychotics although the prescription of typical
antipsychotics still dominates.
Introduction
Up to 80% of all antipsychotics are reported to be prescribed
in primary care [1–5]. Furthermore, 1–3.2% of general practice
patients receive antipsychotic drugs when investigated cross-
sectionally and in approximately 10% of the general practitioner–
patient encounters in which a psycho-active drug is prescribed an
antipsychotic is among the prescribed drugs [2,4,6–8]. Thus, pre-
scription of antipsychotics seems relatively common in general
practice. Antipsychotics may induce serious side effects such as
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tardive dyskinesia, Parkinsonism, akathisia, weight gain and
sedation and enhance the risk of cerebrovascular incidents in
some patient groups. Consequently, there has been concern about
off-label use (Off-label use is defined as the use of a drug outside
the licensed indication) of antipsychotics [1,6,9–12]. Although
off-label use can partly be attributed to following guidelines based
on proof from large randomized controlled trials, minimal evi-
dence may support other off-label use. It is estimated that 30–
50% of all prescriptions of antipsychotics are for off-label use
[1,6,9,11]. However, it is largely unknown what conditions give
rise to off-label antipsychotic prescribing by general practitioners
(GPs). To investigate possible motives for off-label prescription,
we associated six pre-defined diagnostic categories, four of them
being off-label indications for antipsychotic treatment in the Neth-
erlands, with new antipsychotic use in a case–control study using
anonymous electronic medical records and pharmacy prescription
data from a large population of GP patients in the Netherlands.
Methods
Database
Data were derived from the Almere Health Care Medical database,
consisting of patients registered with approximately 110 GPs in
20 general practices in Almere in the Netherlands. Between 1999
and 2003, the population contributing to the database increased
from 109 946 to 164 008 patients, thus representing a growing,
large and dynamic population. GPs received training in systematic
data entry and were financially compensated for providing data.
Health problems and diagnoses were coded according to the Inter-
national Classification of Primary Care (ICPC), version I with
Dutch subtitles (2000) [13]. Linkage to pharmacy data from 17
pharmacies in the form of Anatomical Therapeutical Chemical
Classification System-codes enabled the study of prescribing in
relation to diagnosis.
Cases
Cases had to be registered in the database between 1 February
1999 and 31 December 2003 and be prescribed an antipsychotic by
a GP, after a minimum of 12 months in which no antipsychotics
were prescribed. By doing so, we selected cases of new antipsy-
chotic prescribing which were then being arbitrarily defined.
Controls
Random selection of controls was done likewise. Only patients
with whatever new medication prescription, except for antipsy-
chotic prescriptions, were eligible. Like in cases, new medication
prescribing was defined as the absence of a prescription of the
same medication in the preceding 12 months. We aimed at select-
ing five controls per case to enhance precision of the association
measure.
Exposure assessment
Prior to the analyses, health problems and diagnoses were selected
that were hypothesized to be reasons for antipsychotic prescribing.
This was done on content grounds while consulting two GPs.
Subsequently, we clustered the selected ICPC codes in six diag-
nostic categories (see Table 1). ‘Depression and anxiety’, ‘sleep-
ing disorders’, ‘acute stress and surmenage’ and ‘dementia’ are the
four diagnostic categories that are off-label reasons for anti-
psychotic treatment. ‘Somatic indications’ is a diagnostic category
consisting of three somatic symptoms that may or may not con-
stitute an approved indication for antipsychotic therapy, depending
on the symptoms’ severity and lack of earlier response to other
than antipsychotic treatment. ‘Psychosis’ is the obvious on-label
indication for the use of antipsychotics. This category was invoked
to validate our data as it was expected to be highly associated with
antipsychotic prescribing. Only ICPC codes recorded within an
arbitrary time frame of -7 to +7 days around the prescription date
were included. In case of two concurrent ICPC categories detected
at one prescription occasion, the ICPC category diagnosed closest
to the prescription date was selected.
Data analysis
Data were processed and analysed using spss 12.0 and Microsoft
Excel SR-2. The yearly incidence of new antipsychotic prescribing
was estimated as the number of cases in a particular year, divided
by the number of persons in the database at the midpoint of that
year. The incidence estimates per year were subsequently averaged
over the total study period.
Logistic regression was used to calculate odds ratios (ORs) as
measures of relative risk of the prescribing of antipsychotics
for the diagnostic categories, while correcting for the potentially
confounding variables age, gender and insurance status [14,15].
The reference category consisted of patients for which only ICPC
codes other than the codes belonging to diagnostic categories
under study were recorded or no ICPC code at all. The ORs were
supplied with a 95% confidence interval (95% CI) as a measure
of precision.
Results
A total of 2809 patients were identified as users of antipsychotics
in the database. We excluded 1279 patients with less than 12
months of antipsychotic-free follow-up since 1 February 1999 and
789 patients because the new prescription was not performed by a
GP. The remaining 723 cases were all included. Subsequently,
3615 controls were selected.
The incidence of initiating antipsychotic therapy was 1.28 per
1000 persons per year (95% CI: 1.09, 1.48). A frequency distribu-
tion of the different antipsychotic medications is shown in Fig. 1.
It demonstrates that typical antipsychotics represent the vast
majority of newly inititiated antipsychotic therapies (90.7%). The
proportion of atypical antipsychotics increased over time from
4.7% in 2000 to 14.4% in 2003. Table 2 shows that the proportions
of female gender and private insurance status are larger in controls
than in cases. It further shows that mean age was substantially
higher in the cases.
In 47.7% and 47.6% of cases and controls, respectively, no
ICPC code was registered in the 14-day time interval (-7 days, +7
days) around the prescription date.
The logistic regression analysis showed substantially elevated
probabilities of prescription for each diagnostic category com-
pared with the reference category (Table 3). The ORs were all
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statistically significant, also after adjustment for the potential
confounders. Changes in the ORs after adjustment were largely
attributable to age. As expected, the OR for the validation category
‘psychosis’ was the highest. Excluding cases and controls in which
no ICPC codes were registered resulted in slightly higher ORs
for all categories (data not shown).
Discussion
Summary of main findings
Four ICPC diagnostic categories that have no approved indications
for antipsychotic treatment in the Netherlands, that is, ‘anxiety and
depression’, ‘acute stress and surmenage’, ‘sleeping disorder’ and
‘dementia’, were moderately to strongly associated with initiating
antipsychotic therapy. In approximately half of the patients that
were prescribed antipsychotics, no ICPC code was registered. The
overall incidence of new antipsychotic prescribing was low, that is,
1.28 per 1000 person-years. Furthermore, GPs mainly prescribed
typical antipsychotics; however, the incidence of initiating treat-
ment with an atypical antipsychotic increased almost threefold
over the study period.
Strengths and limitations
The high relative risk of prescription for the psychosis category
supports the validity of our results. A further strength is that
despite the relatively small numbers of patients in the diagnostic




codes Full ICPC description
Psychosis P20.4 Hallucinations/delusions
P71.0 Other organic psychosis
P71.1 Organic amnestic syndrome (excluding alcohol)
P71.3 Other organic psychosis









P98.0 Other not specified psychoses
P98.2 Other not specified psychoses
P99.0 Puerperal psychoses
Depression and anxiety P01 Feeling anxious/nervous/tense
P03 Feeling depressed
P74 Anxiety disorder/anxiety state
P76.0 Depressive disorder
P76.1 Reactive depression
P76.2 Other depressive disorder
Sleeping disorders P06 Sleep disturbance
Acute stress and
surmenage
P02.0 Acute stress reaction
P02.1 Reaction to bereavement
P02.2 Reaction to violence
P02.3 Other acute stress reaction
P78.0 Neuraesthenia/surmenage
P78.1 Hyper aesthetic emotional syndrome
P78.2 Other form of neuraesthenia/surmenage
Dementia P70.0 Senile dementia/Alzheimer
P70.1 Alzheimer’s disease
P70.2 Arteriosclerotic/multi-infarct dementia
P70.3 Dementia as a consequence of another specific disorder
P70.4 Other dementia
P20.1 Orientation in time/place/person disturbed
P20.2 Attention/concentration disorders
P20.3 Amnesia all forms
Somatic indications D09 Nausea
D10 Vomiting
R29.1 Hiccups
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categories, the associations observed were fairly strong and all
statistically significant.
The limitations of this study are largely inherent to the use of
retrospectively collected health care data. The database did not
provide information explicitly stating that the recorded ICPC
codes were the reasons for prescribing antipsychotics, nor did
it provide information about the past evolution and severity of the
recorded problems, or about unregistered coexisting problems.
Therefore, there could be other relevant reasons for GPs to pre-
scribe antipsychotics explaining the association between the pre-
scription and the analysed ICPC codes. However, we feel that the
relations are likely to be largely real as in 84.6% of cases and
controls where an ICPC code was registered, the day of registra-
tion coincided with the date of antipsychotic prescribing. Further-
more, a sensitivity analysis excluding all none-coinciding ICPC
codes yielded higher risks for all categories in both adjusted and
non-adjusted analyses.
The 12-month antipsychotics-free period prior to prescription,
defining initiation of antipsychotic therapy, may have been too
short. However, it seems unlikely that intermittent antipsychotic
use was materially classified as new use because in only 4.8% of
the cases a subsequent second antipsychotic-free period of at least
12 months was identified within the study period. Nonetheless, a
source of bias may be that in 18 cases (2.5%) and in 253 controls
(7.1%), the GP indicated it was a repeat prescription, even though
there was a 12-month antipsychotic-free period preceding it.
Because of the lack of clarity regarding the rules for registration
of the indication ‘repeat’ by the GP, we ignored it in the selection
of our cases and controls. A sensitivity analyses excluding these
as ‘repeat’ marked prescription instances in cases and controls
yielded similar ORs for all categories (data not shown).
Figure 1 Bar chart showing the percentages
of antipsychotics newly prescribed by the
general practitioners in the cases. Different
combinations (n = 7) of up to three different
typical antipsychotics (n = 10), clozapine
(n = 2), penfluridol (n = 6), periciazine (n = 6),
perphenazine (n = 1), quetiapine (n = 1),
sulpiride (n = 6), tetrabenazine (n = 1) and
tiapride (n = 1) were combined to the cat-
egory ‘other (<1%)’ as they were each pre-
scribed in less then 1% of the cases.
Table 2 Characteristics of cases and controls
Variables Controls (n = 3615) Cases (n = 723)
Age, mean (range) 40.2 (1–101) 56.3 (0–101)
Gender
Female, n (%) 2234 (61.8) 353 (48.8)
Insurance status, n (%)
Private insurance 1068 (29.5) 151 (20.9)
State insurance 2547 (70.5) 572 (79.1)
Diagnostic categories, n (%)
Psychosis 2 (0.1) 69 (9.5)
Depression and anxiety 46 (1.3) 30 (4.1)
Sleeping disorders 16 (0.4) 9 (1.2)
Acute stress and surmenage 15 (0.5) 7 (1.0)
Dementia 2 (0.1) 29 (4.0)
Somatic indications 16 (0.4) 40 (5.5)
Other ICPC codes diagnosed 1799 (49.8) 203 (28.1)
No ICPC code diagnosed 1719 (47.6) 345 (47.7)
Table 3 Crude and adjusted odds ratios (OR) with 95% confidence




OR (95% CI) OR (95% CI)
Psychosis 225.2 (55.0, 921.2) 170.7 (41.3, 705.9)
Depression and anxiety 4.3 (2.7, 6.8) 4.5 (2.8, 7.4)
Sleeping disorders 3.7 (1.6, 8.4) 3.5 (1.4, 8.4)
Acute stress and surmenage 3.0 (1.2, 7.5) 3.6 (1.4, 9.1)
Dementia 94.6 (22.5, 397.8) 42.9 (9.7, 190.5)
Somatic indications 16.3 (9.1, 29.3) 17.5 (9.4, 32.6)
*Adjusted for age, gender and insurance status.
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Some of the approved indications for antipsychotics in the Neth-
erlands, that is, agitation and restlessness and severe and treatment
refractory anxiety, do not have separate ICPC codes in the Dutch
ICPC registration systems. Obviously, the ICPC registration
system is not designed specifically for registration of approved
indications for antipsychotic treatment, but has to cover, mostly in
more general terms, the entire spectrum of diagnoses and symp-
toms that can be encountered in the general practice. However, as
the two mentioned approved indications for prescription of anti-
psychotics could coincide with any of the aforementioned four
off-label diagnostic categories, especially ‘dementia’ and ‘depres-
sion and anxiety’, the relative risks for these categories may have
been overestimated. Other reasons for recording one of the off-
label categories could be reluctance to diagnose psychosis or
incomplete skills or confidence for diagnosing and treating mental
disorders [16,17].
In view of the above, it seems likely that our results reflect, at
least partially, either off-label prescribing or incomplete registra-
tion or a combination of these factors.
A clear preference for prescribing typical antipsychotics, as
opposed to atypical antipsychotics, was observed. This is in line
with the guidelines of the Dutch College of General Practitioners
(NHG) recommending typical antipsychotics as a first line of
treatment [18].
Comparison with existing literature
The estimated incidence of the GP initiating antipsychotic treat-
ment in the present study was 1.3 per 1000 person-years. Previ-
ously published studies reported higher rates of initiation of
antipsychotic therapy by the GP, 3.3 and 10.1 per 1000 person-
years, respectively [10,14,19]. When we included new antipsy-
chotic prescriptions registered by any doctor, and not only by
the GP, a higher incidence of 2.7 new prescriptions per 1000
person-years (95% CI: 2.40, 2.97) was found.
The population in Almere is relatively young in comparison
with the general population in the Netherlands (source: Statistics
Netherlands, Voorburg/Heerlen) while antipsychotics are more
often prescribed to elderly people, as is reflected in the mean age
shown in Table 2 [7]. When we projected our incidence rate to the
age distribution of the general population in the Netherlands, the
rate of new antipsychotic prescription by GPs was 1.69 per 1000
person-years (95% CI: 1.48, 1.91).
Our finding of considerable off-label prescribing of anti-
psychotics by GPs is consistent with previous work. A study by
Mortimer showed that in the majority of cases, it was impossible to
ascertain a diagnosis that suggested the need for antipsychotic
treatment, despite professionals scrutinizing case notes and per-
forming personal enquiries of the GPs [6]. A small retrospective
Dutch study using questionnaires found that in 11% of the cases
that used antipsychotics, in six general practices, the diagnosis
was unknown [1]. The latter study also found that at least 76.9%
of women and 40% of men were prescribed antipsychotics for
approved indications, in case the GP made the diagnosis and
initiated antipsychotic drug therapy, while in our study in 15.1% of
all cases an on-label diagnosis was registered. In this study, the
percentage increased to 28.8 if those cases were included where
any ICPC code was registered and to 33.6 if additionally the date
of registration and that of prescription coincided. One study per-
formed in UK, including 200 randomly selected first-time users of
antipsychotics of 10–99 years old, found that more than half of all
incident antipsychotic use in the general practice was for non-
approved indications such as depression, anxiety states and
panic disorder, 15% for agitation and dementia, and less than 10%
for the treatment of schizophrenia and other psychoses [19].
This study excluded less frequently prescribed antipsychotics. In
agreement with our study, Trifiró et al. [10] reported that anxiety
disorders were the most common off-label reason to prescribe
typical antipsychotics in a general practice database.
The preference of the GP for prescribing typical antipsychotics
in the present study (90% of the prescriptions) is consistent with
the finding of Hamann et al., who found 77% of typical antipsy-
chotic first prescriptions, while, unlike the present study, prescrip-
tion of low-potency antipsychotics and depot administrations were
excluded from the analyses [3].
A UK study concerning the years 2000 and 2001 found that
olanzapine and risperidone were the most frequently prescribed
atypical medications, 45% and 38%, respectively (37.3% and
58.2% in our study, respectively) [20]. The proportion of initiated
therapy with atypical antipsychotics by the GP increased almost
threefold over the years 2000 (4.7%) to 2003 (14.4%) in the
present study, consistent with incidence rates in Italy that
increased similarly from 0.4 per 1000 person-years in 1999 to 1.3
per 1000 person-years in 2002 [10].
Implications for future research or
clinical practice
Our results enforce the need for future prospective studies in
general practice to prompt GPs to enter a diagnosis and an ICPC
code at the moment of each prescription of antipsychotics, and
simultaneously indicate any problem experienced in allocating
proper ICPC codes to the patient. This will provide more robust
data to confirm or disprove off-label prescribing of antipsychotics
by the GP.
Conclusion
General practitioners do not often initiate antipsychotic therapy.
In this study it seemed that, when initiating such treatment, the GP
partially did this for off-label indications. Furthermore, at initia-
tion of antipsychotic therapy there was no registration of an ICPC
code in 50% of the cases, despite the rareness of the occasion and
the severity of the approved indications for antipsychotic treat-
ment. GPs preferred to prescribe typical rather than atypical antip-
sychotics, yet the proportion of initiated atypical antipsychotic
therapy increased threefold from 2000 to 2004.
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